Lv4
540 积分 2025-04-22 加入
Reply to “High Pharmacokinetic Variability and Unrecognized Limitations in First‐Line Osimertinib Plus Chemotherapy for EGFR‐Mutated NSCLC”
6天前
已完结
Osimertinib with Chemotherapy in EGFR -Mutated NSCLC
6天前
已完结
High Pharmacokinetic Variability and Unrecognized Limitations in First‐Line Osimertinib Plus Chemotherapy for EGFR‐Mutated NSCLC
6天前
已完结
Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14C]‐Belumosudil in Healthy Men: A Phase 1, Open‐Label, 2‐Part Study
7天前
已完结
The Combination of Exposure‐Response and Case‐Control Analyses in Regulatory Decision Making
26天前
已完结
The Combination of Exposure‐Response and Case‐Control Analyses in Regulatory Decision Making
26天前
已完结
A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a 14C‐microdose approach
1个月前
已完结
Determination of absolute bioavailability, absorption, metabolism, and excretion of evogliptin in healthy male subjects using a microtracer method
1个月前
已完结
The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor
1个月前
已完结
皖公网安备34019202002308
